Biostar, to spur the placental stem cell storage business

  • The chance for storing placental stem cell comes only once in your lifetime
  • A treasure trove for the future regenerative medicine technologies to overcome cerebral palsy, Alzheimer’s and degenerative arthritis

Biostar, the adult stem cell bank co-managed by Nature Cell that represents Korea, announced its decision to spur its placental stem cell storage business. Biostar is a comprehensive stem cell bank founded based on core patents and technologies related with placental-derived stem cells and adipose-derived stem cells.

Placenta is a tissue specially formed for an embryo during pregnancy. It helps the embryo to grow, functions as the embryo’s underdeveloped heart, lungs, liver and kidneys, and prevents harmful substances from entering the system. In particular, amnion, one of the parts consisting a placenta, holds mesenchymal stem cells with superior differentiating ability. Compared with cord blood, one thousand times more mesenchymal stem cells can be acquired from amnion. It can be stored only once in each person’s life time, that is, upon birth. Collecting stem cells from amnion does not cause any stress to the infant or the mother, because they can be collected from the placenta which naturally comes out after birth.

Using its unparalleled adult stem cell cultivation technology, Biostar is the only stem cell bank in the world to operate a system which cultures and stores stem cells. The large amount of placental stem cells thus cultured and stored can be used by immediate family members sharing genetic similarity, to treat diseases caused by cell damage or other immune diseases.

In addition, Biostar has gained recognition for its technological expertise related with storage and use of adult stem cell, through publication of various international papers and its core patents. As of December 2014, the company published a total of 49 articles in international journals such as <Stem Cells>,<PLoS ONE>,<Stem Cells DeV>. As for patents, it filed 95 applications, and had 36 patents registered (when confined to patents related with placenta stem cells, 23 applications have been filed, and 12 patents have been registered)

Leave a reply